Trial
NCT05038878
An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
AbbVie
Condition
Mild Autonomous Cortisol Excess
Intervention
Elagolix
Why stopped
Difficulty recruiting patients
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-18